Synthesis, identification and in vivo studies of tumor-targeting agent peptide doxorubicin (PDOX) to treat peritoneal carcinomatosis of gastric cancer with similar efficacy but reduced toxicity

Table 1 The ePCI score at survival endpoint in 4 groups of rabbits [range (median)]

	Control (n = 10)	HIPEC (n = 10)	PDOX (n = 10)	DOX (n = 10)
The ePCI score in different regions
Region I	0 ~ 3 (3)	0 ~ 3 (2)	0 ~ 3 (0)	0 ~ 3 (0)
Region II	3 ~ 3 (3)	3 ~ 3 (3)	3 ~ 3 (3)	3 ~ 3 (3)
Region III	1 ~ 3 (3)	0 ~ 3 (3)	0 ~ 3 (1)	0 ~ 3 (1)
Region IV	0 ~ 3 (3)	0 ~ 3 (1)	0 ~ 3 (0)	0 ~ 3 (0)
Ascites (mL)*	12.0 ~ 113.4 (56.0)	0.0 ~ 94.0 (18.1)	0.0 ~ 0.0 (0.0)	0.0 ~ 0.0 (0.0)
The ePCI score^§	7 ~ 13 (11)	5 ~ 12 (9)	3 ~ 9 (6)	3 ~ 9 (6)

*Ascites: p = 0.323, HIPEC vs. Control; p < 0.001, PDOX vs. HIPEC; p < 0.001, DOX vs. HIPEC.
^§The ePCI score: p = 0.073, HIPEC vs. Control; p = 0.020, PDOX vs. HIPEC; p = 0.020, DOX vs. HIPEC; p = 0.474, PDOX vs. DOX.

ISSN: 1476-4598